Testing RSV vaccine in people with weakened immune systems
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have had a stem cell transplant, CAR-T therapy, or certain organ transplants at least 90 days ago.
- Or you are 60 or older (or 50–59 with higher risk for RSV) and not immunocompromised.
- You must be generally healthy enough to attend study visits for one year.
- You cannot have received any RSV vaccine or RSV antibody treatment before.
- You must not be pregnant or breastfeeding, and use birth control if needed.
- You must not have certain recent illnesses, treatments, or severe allergies that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial studies how well the RSV vaccine works in people who have had a stem cell transplant or CAR-T therapy for a blood cancer. It aims to see if the vaccine can protect you from RSV, a common respiratory virus that can be serious for people with weakened immune systems.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.